Company: RPID
Filing Date: 2025-04-08
Form Type: DEF 14A
Source: 0001380106-25-000089
Chunk: 31

Company: RAPID MICRO BIOSYSTEMS, INC.
Filing Date: 2025-04-08
Form: DEF 14A
Chunk 31
---
 overseeing the work of our independent registered public accounting firm, including through the receipt and consideration of reports from such firm; • reviewing and discussing with management and the independent registered public accounting firm our annual and quarterly financial statements and related disclosures as well as critical accounting policies and practices used by us; • coordinating our Board’s oversight of our internal control over financial reporting, disclosure controls and procedures and code of business conduct and ethics; • discussing our risk assessment and risk management policies, including the process by which our exposure to risk is handled, and overseeing the management of our financial and cybersecurity risks; 18

#### TABLE OF CONTENTS
• meeting independently with our internal auditing staff, if any, independent registered public accounting firm and management;

• reviewing and approving or ratifying any related person transactions; and

• preparing the audit committee report required by SEC rules.

The Audit Committee charter is available on our website at investors.rapidmicrobio.com. The members of our Audit Committee are Melinda Litherland, Richard Kollender and Inese Lowenstein. Ms. Litherland serves as the Chair of the committee. All members of our Audit Committee meet the requirements for financial literacy under the applicable listing rules of Nasdaq, or the Nasdaq rules. Upon annual review in February 2025, our Board determined that each of Mses. Litherland and Lowenstein and Mr. Kollender meet the independence requirements of the Nasdaq rules for audit committee purposes and the independence requirements of Rule 10A-3 under the Exchange Act. Our Board has determined that each of Ms. Litherland and Mr. Kollender is an “audit committee financial expert” as defined by applicable SEC rules and have the requisite financial sophistication as defined under the applicable Nasdaq rules.

The Audit Committee met five (5) times during the fiscal year ended December 31, 2024.

<div align='center'>19</div>

#### TABLE OF CONTENTS

### COMPENSATION COMMITTEE
The Compensation Committee’s responsibilities include, among other things:

• reviewing and making recommendations to our Board with respect to the compensation of our Chief Executive Officer;

• reviewing and approving the compensation of our other executive officers;

• overseeing and administering our cash and equity incentive plans;

• reviewing and making recommendations to our Board with respect to director compensation;

• approving the retention of any consultants, legal counsel or other advisors to assist in the evaluation of compensation matters;

• overseeing the application of our Compensation Recovery Policy;

• reviewing and discussing annually with management our executive compensation disclosures to the